Compare WIX & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIX | NUVL |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 7.1B |
| IPO Year | 2013 | 2021 |
| Metric | WIX | NUVL |
|---|---|---|
| Price | $106.38 | $101.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 14 |
| Target Price | ★ $184.00 | $134.29 |
| AVG Volume (30 Days) | ★ 1.9M | 711.2K |
| Earning Date | 11-19-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.59 | N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,929,230,000.00 | N/A |
| Revenue This Year | $14.50 | N/A |
| Revenue Next Year | $14.24 | N/A |
| P/E Ratio | $44.11 | ★ N/A |
| Revenue Growth | ★ 13.22 | N/A |
| 52 Week Low | $92.23 | $55.54 |
| 52 Week High | $247.11 | $112.88 |
| Indicator | WIX | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 47.10 |
| Support Level | $97.12 | $103.52 |
| Resistance Level | $108.70 | $107.99 |
| Average True Range (ATR) | 4.71 | 3.14 |
| MACD | 1.99 | -1.21 |
| Stochastic Oscillator | 82.10 | 13.02 |
Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves, or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years has invested heavily and introduced its Wix Studio offering for partners, who are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.